Immunoadoptive Cell Therapy Private Limited - Company Profile

It is a healthcare private limited company based in Thane, Maharashtra, India, established in 2018.
2018 Thane, Maharashtra, India Active
Last Updated:
Access Report
About Immunoadoptive Cell Therapy Private Limited

Immunoadoptive Cell Therapy Private Limited, a active private limited company, was established on 08 October 2018 in Thane, Maharashtra, India. Engaging in preventive health services within the professional, scientific and technical sector, it holds CIN: U74999MH2018PTC315497. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹4.90 M and a paid-up capital of ₹0.20 M.

It upholds a compliant status. Employing 69 professional, Its leadership includes Shirish Arya (Director), Atharva Ajay Karulkar (Director), Shalini Rahul Purwar (Whole-Time Director). Past directors included Shirish Arya, Alka Dwivedi, Atharva Ajay Karulkar. Its latest AGM occurred on 12 June 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No.D-222/26,Ttc Industrial Area, Midc,Village Shiravane,Navi Mumbai, Thane, Maharashtra, 400706.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U74999MH2018PTC315497

  • Registration Number

    315497

  • Incorporation Date

    08 October 2018

  • Authorized Capital

    ₹4.90 M

  • Paid-Up Capital

    ₹0.20 M

  • ROC Code

    Roc Mumbai

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 4.90 M
  • Paid Up Capital ₹ 0.20 M
  • Company Age 7 Year, 4 Months
  • Last Filing with ROC 31 Mar 2025
  • Revenue Growth **** 1454.31%
  • Profit Growth **** -46.60%
  • Ebitda **** -92.92%
  • Net Worth 157.06%
  • Total Assets **** 153.42%
Company report

Immunoadoptive Cell Therapy Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Immunoadoptive Cell Therapy Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report Banner Element
Who are the key members and board of directors at Immunoadoptive Cell Therapy Private Limited?
Current Directors
Name Designation Appointment Date Status
Shirish Arya Director 06 Aug 2021 Current
Atharva Ajay Karulkar Director 29 Oct 2021 Current
Shalini Rahul Purwar Whole-Time Director 08 Oct 2018 Current
Rahul Purwar Director 08 Oct 2018 Current
Chava Satyanarayana Nominee Director 09 Dec 2021 Current
Ravindranath Kancherla Nominee Director 09 Dec 2021 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Additional Director 30 Nov 2021 Past
Pramod Abcsdd Director 05 Sep 2021 Past
Pramod Abcsdd Additional Director 30 Nov 2021 Past
Pramod Abcsdd Director 21 Jul 2024 Past
Pramod Abcsdd Director 12 Feb 2024 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Immunoadoptive Cell Therapy.

Immunoadoptive Cell Therapy Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 1454.31% increase. The company also saw a substantial fall in profitability, with a 46.6% decrease in profit. The company's net worth Soared by an impressive increase of 157.06%.

Immunoadoptive Cell Therapy revenue growth over time
Immunoadoptive Cell Therapy profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 1454.31%
*******
*******
*******
*******
Revenue from Operations
*******
 3226.75%
*******
*******
*******
*******
Total Assets
*******
 153.42%
*******
*******
*******
*******
Profit or Loss
*******
 -46.60%
*******
*******
*******
*******
Net Worth
*******
 157.06%
*******
*******
*******
*******
EBITDA
*******
 -92.92%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Immunoadoptive Cell Therapy?

In 2024, Immunoadoptive Cell Therapy had a public holding of 17.59%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Immunoadoptive Cell Therapy?

Immunoadoptive Cell Therapy has a workforce of 69 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Immunoadoptive Cell Therapy, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immunoadoptive Cell Therapy's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Immunoadoptive Cell Therapy
Recent Activity within the Organization
  • Annual General Meeting

    Immunoadoptive Cell Therapy Private Limited last Annual general meeting of members was held on 12 Jun 2025 as per latest MCA records. was recorded as a recent event.

  • Balance Sheet

    The activity Immunoadoptive Cell Therapy Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was completed.

  • Director Appointment

    The activity Chava Satyanarayana was appointed as a Nominee Director was appointed as a Nominee Director on 09 Dec 2021 & has been associated with this company since 4 years 2 months . was completed.

  • Director Appointment

    Ravindranath Kancherla was appointed as a Nominee Director was appointed as a Nominee Director on 09 Dec 2021 & has been associated with this company since 4 years 2 months . was recorded as a recent event.

  • Director Appointment

    Atharva Ajay Karulkar was appointed as a Director was appointed as a Director on 29 Oct 2021 & has been associated with this company since 4 years 3 months . was recorded as a recent event.

  • Director Appointment

    Progress on Shirish Arya was appointed as a Director was appointed as a Director on 06 Aug 2021 & has been associated with this company since 4 years 6 months . was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Immunoadoptive Cell Therapy Private Limited?

The CIN of Immunoadoptive Cell Therapy Private Limited is U74999MH2018PTC315497.

Where is Immunoadoptive Cell Therapy Private Limited headquartered?

Immunoadoptive Cell Therapy Private Limited is headquartered at Plot No.D-222/26,Ttc Industrial Area, Midc,Village Shiravane,Navi Mumbai, Thane, Maharashtra, 400706.

When was Immunoadoptive Cell Therapy Private Limited incorporated?

Immunoadoptive Cell Therapy Private Limited was incorporated on 08 October 2018.

Who are the current directors of Immunoadoptive Cell Therapy Private Limited?

The current directors of Immunoadoptive Cell Therapy Private Limited are

What is the primary industry of Immunoadoptive Cell Therapy Private Limited?

The primary industry of Immunoadoptive Cell Therapy Private Limited is Professional, Scientific And Technical.

Is Immunoadoptive Cell Therapy Private Limited a listed company?

Immunoadoptive Cell Therapy Private Limited is unlisted.

What is the capital structure of Immunoadoptive Cell Therapy Private Limited?

The authorized capital of Immunoadoptive Cell Therapy Private Limited is ₹4.90 M, and the paid-up capital is ₹0.20 M.

What is the compliance status of Immunoadoptive Cell Therapy Private Limited?

The compliance status of Immunoadoptive Cell Therapy Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available